APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cytomegalovirus (CMV) Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Cytomegalovirus (CMV) Vaccine Market Outlook and Growth Opportunities 2026

30 December 2025196 pages

Choose your research edition.

Industry ResearchCytomegalovirus (CMV) Vaccine Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Cytomegalovirus (CMV) Vaccine Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Cytomegalovirus (CMV) Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032175 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cytomegalovirus (CMV) Vaccine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Cytomegalovirus (CMV) Vaccine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Cytomegalovirus (CMV) Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Cytomegalovirus (CMV) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Cytomegalovirus (CMV) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Cytomegalovirus (CMV) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Cytomegalovirus (CMV) Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Cytomegalovirus (CMV) Vaccine market include AlphaVax, Moderna, Merck and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Cytomegalovirus (CMV) Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Cytomegalovirus (CMV) Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Cytomegalovirus (CMV) Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Cytomegalovirus (CMV) Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Cytomegalovirus (CMV) Vaccine Segment by Company

AlphaVax

Moderna

Merck

Novartis

Cytomegalovirus (CMV) Vaccine Segment by Type

Attenuated Vaccines

Subunit Vaccines

Cytomegalovirus (CMV) Vaccine Segment by Application

Laboratories

Hospitals

Diagnostic Centers and Clinics

Others

Cytomegalovirus (CMV) Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Cytomegalovirus (CMV) Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Cytomegalovirus (CMV) Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Cytomegalovirus (CMV) Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Cytomegalovirus (CMV) Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cytomegalovirus (CMV) Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cytomegalovirus (CMV) Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cytomegalovirus (CMV) Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Cytomegalovirus (CMV) Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Cytomegalovirus (CMV) Vaccine industry.

Chapter 3: Detailed analysis of Cytomegalovirus (CMV) Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Cytomegalovirus (CMV) Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Cytomegalovirus (CMV) Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Cytomegalovirus (CMV) Vaccine Industry Trends Table 2. Cytomegalovirus (CMV) Vaccine Industry Drivers Table 3. Cytomegalovirus (CMV) Vaccine Industry Opportunities and Challenges Table 4. Cytomegalovirus (CMV) Vaccine Industry Restraints Table 5. Global Cytomegalovirus (CMV) Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Cytomegalovirus (CMV) Vaccine Revenue Share by Company (2021-2026) Table 7. Global Cytomegalovirus (CMV) Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Cytomegalovirus (CMV) Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Cytomegalovirus (CMV) Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Cytomegalovirus (CMV) Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Cytomegalovirus (CMV) Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Cytomegalovirus (CMV) Vaccine Company, Product Type & Application Table 13. Global Cytomegalovirus (CMV) Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Cytomegalovirus (CMV) Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Attenuated Vaccines Table 18. Significant Companies of Subunit Vaccines Table 19. Global Cytomegalovirus (CMV) Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Cytomegalovirus (CMV) Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Cytomegalovirus (CMV) Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Cytomegalovirus (CMV) Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Cytomegalovirus (CMV) Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Cytomegalovirus (CMV) Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Cytomegalovirus (CMV) Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Cytomegalovirus (CMV) Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Cytomegalovirus (CMV) Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Cytomegalovirus (CMV) Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Laboratories Table 30. Significant Companies of Hospitals Table 31. Significant Companies of Diagnostic Centers and Clinics Table 32. Significant Companies of Others Table 33. Global Cytomegalovirus (CMV) Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Cytomegalovirus (CMV) Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Cytomegalovirus (CMV) Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Cytomegalovirus (CMV) Vaccine Sales Volume Share by Application (2021-2026) Table 37. Global Cytomegalovirus (CMV) Vaccine Sales Volume Share by Application (2027-2032) Table 38. Global Cytomegalovirus (CMV) Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Cytomegalovirus (CMV) Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Cytomegalovirus (CMV) Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Cytomegalovirus (CMV) Vaccine Sales Value Share by Application (2021-2026) Table 42. Global Cytomegalovirus (CMV) Vaccine Sales Value Share by Application (2027-2032) Table 43. Global Cytomegalovirus (CMV) Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Cytomegalovirus (CMV) Vaccine Sales by Region (2021-2026) & (K Units) Table 45. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Region (2021-2026) Table 46. Global Cytomegalovirus (CMV) Vaccine Sales by Region (2027-2032) & (K Units) Table 47. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Region (2027-2032) Table 48. Global Cytomegalovirus (CMV) Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Cytomegalovirus (CMV) Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Cytomegalovirus (CMV) Vaccine Sales Value Share by Region (2021-2026) Table 51. Global Cytomegalovirus (CMV) Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Cytomegalovirus (CMV) Vaccine Sales Value Share by Region (2027-2032) Table 53. Global Cytomegalovirus (CMV) Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Cytomegalovirus (CMV) Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Cytomegalovirus (CMV) Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Cytomegalovirus (CMV) Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Cytomegalovirus (CMV) Vaccine Sales by Country (2021-2026) & (K Units) Table 58. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Country (2021-2026) Table 59. Global Cytomegalovirus (CMV) Vaccine Sales by Country (2027-2032) & (K Units) Table 60. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Country (2027-2032) Table 61. Global Cytomegalovirus (CMV) Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Cytomegalovirus (CMV) Vaccine Sales Value Market Share by Country (2021-2026) Table 63. Global Cytomegalovirus (CMV) Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Cytomegalovirus (CMV) Vaccine Sales Value Market Share by Country (2027-2032) Table 65. AlphaVax Company Information Table 66. AlphaVax Business Overview Table 67. AlphaVax Cytomegalovirus (CMV) Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. AlphaVax Cytomegalovirus (CMV) Vaccine Product Portfolio Table 69. AlphaVax Recent Development Table 70. Moderna Company Information Table 71. Moderna Business Overview Table 72. Moderna Cytomegalovirus (CMV) Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Moderna Cytomegalovirus (CMV) Vaccine Product Portfolio Table 74. Moderna Recent Development Table 75. Merck Company Information Table 76. Merck Business Overview Table 77. Merck Cytomegalovirus (CMV) Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Merck Cytomegalovirus (CMV) Vaccine Product Portfolio Table 79. Merck Recent Development Table 80. Novartis Company Information Table 81. Novartis Business Overview Table 82. Novartis Cytomegalovirus (CMV) Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Novartis Cytomegalovirus (CMV) Vaccine Product Portfolio Table 84. Novartis Recent Development Table 85. Key Raw Materials Table 86. Raw Materials Key Suppliers Table 87. Cytomegalovirus (CMV) Vaccine Distributors List Table 88. Cytomegalovirus (CMV) Vaccine Customers List Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Cytomegalovirus (CMV) Vaccine Product Image Figure 2. Global Cytomegalovirus (CMV) Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cytomegalovirus (CMV) Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Cytomegalovirus (CMV) Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Cytomegalovirus (CMV) Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Cytomegalovirus (CMV) Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Attenuated Vaccines Image Figure 10. Subunit Vaccines Image Figure 11. Global Cytomegalovirus (CMV) Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Cytomegalovirus (CMV) Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Cytomegalovirus (CMV) Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Cytomegalovirus (CMV) Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Cytomegalovirus (CMV) Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Cytomegalovirus (CMV) Vaccine Sales Value Share by Type (2021-2032) Figure 17. Laboratories Image Figure 18. Hospitals Image Figure 19. Diagnostic Centers and Clinics Image Figure 20. Others Image Figure 21. Global Cytomegalovirus (CMV) Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Cytomegalovirus (CMV) Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Cytomegalovirus (CMV) Vaccine Sales Volume Share by Application (2021-2032) Figure 24. Global Cytomegalovirus (CMV) Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Cytomegalovirus (CMV) Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Cytomegalovirus (CMV) Vaccine Sales Value Share by Application (2021-2032) Figure 27. Global Cytomegalovirus (CMV) Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Cytomegalovirus (CMV) Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Cytomegalovirus (CMV) Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Cytomegalovirus (CMV) Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. North America Cytomegalovirus (CMV) Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Cytomegalovirus (CMV) Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Cytomegalovirus (CMV) Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Cytomegalovirus (CMV) Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Cytomegalovirus (CMV) Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Cytomegalovirus (CMV) Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. South America Cytomegalovirus (CMV) Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Cytomegalovirus (CMV) Vaccine Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Cytomegalovirus (CMV) Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Cytomegalovirus (CMV) Vaccine Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Cytomegalovirus (CMV) Vaccine Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Attenuated Vaccines
  • Subunit Vaccines
Applications
  • Laboratories
  • Hospitals
  • Diagnostic Centers and Clinics
  • Others
Companies covered
  • AlphaVax
  • Moderna
  • Merck
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Cytomegalovirus (CMV) Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Cytomegalovirus (CMV) Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Cytomegalovirus (CMV) Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Cytomegalovirus (CMV) Vaccine Market Dynamics
  1. 2.1 Cytomegalovirus (CMV) Vaccine Industry Trends
  2. 2.2 Cytomegalovirus (CMV) Vaccine Industry Drivers
  3. 2.3 Cytomegalovirus (CMV) Vaccine Industry Opportunities and Challenges
  4. 2.4 Cytomegalovirus (CMV) Vaccine Industry Restraints
3 Cytomegalovirus (CMV) Vaccine Market by Company
  1. 3.1 Global Cytomegalovirus (CMV) Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Cytomegalovirus (CMV) Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Cytomegalovirus (CMV) Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Cytomegalovirus (CMV) Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Cytomegalovirus (CMV) Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Cytomegalovirus (CMV) Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Cytomegalovirus (CMV) Vaccine Company Product Type and Application
  8. 3.8 Global Cytomegalovirus (CMV) Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Cytomegalovirus (CMV) Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Cytomegalovirus (CMV) Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Cytomegalovirus (CMV) Vaccine Market by Type
  1. 4.1 Cytomegalovirus (CMV) Vaccine Type Introduction
  2. 4.1.1 Attenuated Vaccines
  3. 4.1.2 Subunit Vaccines
  4. 4.2 Global Cytomegalovirus (CMV) Vaccine Sales Volume by Type
  5. 4.2.1 Global Cytomegalovirus (CMV) Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Cytomegalovirus (CMV) Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Cytomegalovirus (CMV) Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Cytomegalovirus (CMV) Vaccine Sales Value by Type
  9. 4.3.1 Global Cytomegalovirus (CMV) Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Cytomegalovirus (CMV) Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Cytomegalovirus (CMV) Vaccine Sales Value Share by Type (2021-2032)
5 Cytomegalovirus (CMV) Vaccine Market by Application
  1. 5.1 Cytomegalovirus (CMV) Vaccine Application Introduction
  2. 5.1.1 Laboratories
  3. 5.1.2 Hospitals
  4. 5.1.3 Diagnostic Centers and Clinics
  5. 5.1.4 Others
  6. 5.2 Global Cytomegalovirus (CMV) Vaccine Sales Volume by Application
  7. 5.2.1 Global Cytomegalovirus (CMV) Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Cytomegalovirus (CMV) Vaccine Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Cytomegalovirus (CMV) Vaccine Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Cytomegalovirus (CMV) Vaccine Sales Value by Application
  11. 5.3.1 Global Cytomegalovirus (CMV) Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Cytomegalovirus (CMV) Vaccine Sales Value by Application (2021-2032)
  13. 5.3.3 Global Cytomegalovirus (CMV) Vaccine Sales Value Share by Application (2021-2032)
6 Cytomegalovirus (CMV) Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Cytomegalovirus (CMV) Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Cytomegalovirus (CMV) Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Cytomegalovirus (CMV) Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Cytomegalovirus (CMV) Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Cytomegalovirus (CMV) Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Cytomegalovirus (CMV) Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Cytomegalovirus (CMV) Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Cytomegalovirus (CMV) Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Cytomegalovirus (CMV) Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Cytomegalovirus (CMV) Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Cytomegalovirus (CMV) Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Cytomegalovirus (CMV) Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Cytomegalovirus (CMV) Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Cytomegalovirus (CMV) Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Cytomegalovirus (CMV) Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Cytomegalovirus (CMV) Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Cytomegalovirus (CMV) Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Cytomegalovirus (CMV) Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Cytomegalovirus (CMV) Vaccine Sales Value Share by Country, 2025 VS 2032
7 Cytomegalovirus (CMV) Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Cytomegalovirus (CMV) Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Cytomegalovirus (CMV) Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Cytomegalovirus (CMV) Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Cytomegalovirus (CMV) Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Cytomegalovirus (CMV) Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Cytomegalovirus (CMV) Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Cytomegalovirus (CMV) Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Cytomegalovirus (CMV) Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Cytomegalovirus (CMV) Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Cytomegalovirus (CMV) Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Cytomegalovirus (CMV) Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AlphaVax
  2. 8.1.1 AlphaVax Company Information
  3. 8.1.2 AlphaVax Business Overview
  4. 8.1.3 AlphaVax Cytomegalovirus (CMV) Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AlphaVax Cytomegalovirus (CMV) Vaccine Product Portfolio
  6. 8.1.5 AlphaVax Recent Developments
  7. 8.2 Moderna
  8. 8.2.1 Moderna Company Information
  9. 8.2.2 Moderna Business Overview
  10. 8.2.3 Moderna Cytomegalovirus (CMV) Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Moderna Cytomegalovirus (CMV) Vaccine Product Portfolio
  12. 8.2.5 Moderna Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Cytomegalovirus (CMV) Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck Cytomegalovirus (CMV) Vaccine Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Cytomegalovirus (CMV) Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Cytomegalovirus (CMV) Vaccine Product Portfolio
  24. 8.4.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Cytomegalovirus (CMV) Vaccine Value Chain Analysis
  2. 9.1.1 Cytomegalovirus (CMV) Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Cytomegalovirus (CMV) Vaccine Sales Mode & Process
  6. 9.2 Cytomegalovirus (CMV) Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Cytomegalovirus (CMV) Vaccine Distributors
  9. 9.2.3 Cytomegalovirus (CMV) Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst